Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

[1]  A. Rossi,et al.  The Resolution of Inflammation , 2008, Inflammopharmacology.

[2]  Geoff Bellingan,et al.  Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyΔ12–14 PGJ2 , 2007, Proceedings of the National Academy of Sciences.

[3]  O. Haworth,et al.  Resolving the problem of persistence in the switch from acute to chronic inflammation , 2007, Proceedings of the National Academy of Sciences.

[4]  C. Andry,et al.  Resolvin E1 Regulates Inflammation at the Cellular and Tissue Level and Restores Tissue Homeostasis In Vivo1 , 2007, The Journal of Immunology.

[5]  C. Serhan,et al.  Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  K. Gronert,et al.  Interdependence of lipoxin A4 and heme‐oxygenase in counter‐regulating inflammation during corneal wound healing , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[8]  Charles N. Serhan,et al.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.

[9]  J. Uddin,et al.  Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.

[10]  Charles N. Serhan,et al.  Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.

[11]  C. Svensson,et al.  Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing , 2007, The Journal of experimental medicine.

[12]  E. Israel,et al.  Protectin D1 Is Generated in Asthma and Dampens Airway Inflammation and Hyperresponsiveness1 , 2007, The Journal of Immunology.

[13]  J. Wallace,et al.  Resolution of in flammation: state of the art, definitions and terms , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  I. Fierro,et al.  Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: A novel antioxidative mechanism , 2006, Thrombosis and Haemostasis.

[15]  S. Gay,et al.  Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease—insights and potential therapeutic implications , 2007, Nature Clinical Practice Rheumatology.

[16]  W. Schiemann,et al.  Apoptotic Cells, through Transforming Growth Factor-β, Coordinately Induce Anti-inflammatory and Suppress Pro-inflammatory Eicosanoid and NO Synthesis in Murine Macrophages* , 2006, Journal of Biological Chemistry.

[17]  V. Arroyo,et al.  Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S‐hydroxy‐DHA , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Katherine B Percarpio,et al.  Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. , 2006, Chemistry & biology.

[19]  J. Duffield,et al.  Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury1 , 2006, The Journal of Immunology.

[20]  C. Serhan,et al.  Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression , 2006, Nature Immunology.

[21]  A. Nakajima,et al.  Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Christopher Haslett,et al.  Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis , 2006, Nature Medicine.

[23]  Takao Shimizu,et al.  The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo , 2006, Pharmacological Reviews.

[24]  Yu Lin,et al.  Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat , 2006, Circulation.

[25]  Chengwei He,et al.  Melanoma growth is reduced in fat-1 transgenic mice: Impact of omega-6/omega-3 essential fatty acids , 2006, Proceedings of the National Academy of Sciences.

[26]  K. Weylandt,et al.  Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Serhan,et al.  Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. , 2006, The Journal of Immunology.

[28]  M. Mangino,et al.  Lipoxin biosynthesis in inflammatory bowel disease. , 2006, Prostaglandins & other lipid mediators.

[29]  B. Levy,et al.  RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Yan Lu,et al.  Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes1 , 2006, The Journal of Immunology.

[31]  I. Fierro,et al.  Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly , 2006, Oncogene.

[32]  L. Dong,et al.  Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. , 2006, Kidney international.

[33]  R J Flower,et al.  Prostaglandins, bioassay and inflammation , 2006, British journal of pharmacology.

[34]  Sheng-hua Wu,et al.  Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. , 2006, American journal of respiratory cell and molecular biology.

[35]  C. Serhan,et al.  The Docosatriene Protectin D1 Is Produced by TH2 Skewing and Promotes Human T Cell Apoptosis via Lipid Raft Clustering* , 2005, Journal of Biological Chemistry.

[36]  R. Alon,et al.  Immune cell migration in inflammation: present and future therapeutic targets , 2005, Nature Immunology.

[37]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[38]  L. Palmer,et al.  Diminished lipoxin biosynthesis in severe asthma. , 2005, American journal of respiratory and critical care medicine.

[39]  I. Fierro,et al.  Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. , 2005, American journal of physiology. Cell physiology.

[40]  Makoto Arita,et al.  Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Charles N. Serhan,et al.  Molecular circuits of resolution: formation and actions of resolvins and protectins , 2005, The Journal of Immunology.

[42]  N. Maheshwari,et al.  A Role for the Mouse 12/15-Lipoxygenase Pathway in Promoting Epithelial Wound Healing and Host Defense* , 2005, Journal of Biological Chemistry.

[43]  Yan Lu,et al.  Mediator-lipidomics: databases and search algorithms for PUFA-derived mediators. , 2005, Journal of lipid research.

[44]  A. Sher,et al.  Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.

[45]  M. Arnaout,et al.  A synthetic eicosanoid LX‐mimetic unravels host‐donor interactions in allogeneic BMT‐induced GvHD to reveal an early protective role for host neutrophils , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  J. Parkinson,et al.  A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B. Rasmusson,et al.  Differential inside-out activation of beta2-integrins by leukotriene B4 and fMLP in human neutrophils. , 2004, Experimental cell research.

[48]  P. Ridker,et al.  Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Serhan.  A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution , 2004, Histochemistry and Cell Biology.

[50]  D. Gilroy,et al.  15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation , 2004, The Journal of experimental medicine.

[51]  P. Mukherjee,et al.  Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Adriano G. Rossi,et al.  Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.

[53]  J. Uddin,et al.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.

[54]  A. Sher,et al.  Exogenous Pathogen and Plant 15-Lipoxygenase Initiate Endogenous Lipoxin A4 Biosynthesis , 2004, The Journal of experimental medicine.

[55]  J. Mekalanos,et al.  The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Mukherjee,et al.  Neuroprotectin D 1 : A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress , 2004 .

[57]  C. Clish,et al.  Reduced Inflammation and Tissue Damage in Transgenic Rabbits Overexpressing 15-Lipoxygenase and Endogenous Anti-inflammatory Lipid Mediators 1 , 2003, The Journal of Immunology.

[58]  Song‐Pyo Hong,et al.  Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-mediated Leukocyte Infiltration and Pro-inflammatory Gene Expression* , 2003, Journal of Biological Chemistry.

[59]  J. Wallace,et al.  A magic bullet for mucosal protection...and aspirin is the trigger! , 2003, Trends in pharmacological sciences.

[60]  C. Serhan,et al.  Aspirin-Triggered Lipoxin A4 and B4 Analogs Block Extracellular Signal-Regulated Kinase-Dependent TNF-α Secretion from Human T Cells 1 , 2003, The Journal of Immunology.

[61]  C. Serhan,et al.  Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells , 2003, The Journal of Biological Chemistry.

[62]  C. Serhan,et al.  Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases , 2003, Journal of dental research.

[63]  P. Wood.  Neuroinflammation : mechanisms and management , 2003 .

[64]  V. Arroyo,et al.  Aspirin (ASA) regulates 5‐lipoxygenase activity and peroxisome proliferator‐activated receptor α‐mediated CINC‐1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA‐triggered 15‐epi‐LXA4 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[65]  A. Simopoulos.  Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases , 2002, Journal of the American College of Nutrition.

[66]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[67]  N. Petasis,et al.  Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. , 2002, Journal of the American Society of Nephrology : JASN.

[68]  C. Serhan,et al.  Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Eugene Y. Kim,et al.  Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4 , 2002, Nature Medicine.

[70]  J. Bousquet,et al.  Lipoxins are potential endogenous antiinflammatory mediators in asthma. , 2002, American journal of respiratory and critical care medicine.

[71]  A. Young,et al.  Lipoxin A4 Analogs Attenuate Induction of Intestinal Epithelial Proinflammatory Gene Expression and Reduce the Severity of Dextran Sodium Sulfate-Induced Colitis1 , 2002, The Journal of Immunology.

[72]  O. Levy,et al.  Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Kutok,et al.  Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). , 2002, The Journal of pharmacology and experimental therapeutics.

[74]  A. Sher,et al.  Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity , 2002, Nature Immunology.

[75]  D. Basile,et al.  Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. , 2001, American journal of physiology. Renal physiology.

[76]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[77]  Charles N. Serhan,et al.  Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.

[78]  S Gelman,et al.  Pathophysiology, Clinical Manifestations, and Prevention of Ischemia-Reperfusion Injury , 2001, Anesthesiology.

[79]  C. Clish,et al.  Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.

[80]  A. Fanning,et al.  Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. , 2000, The Journal of biological chemistry.

[81]  J. Varga,et al.  Lipoxin A4 Inhibits IL-1β-Induced IL-6, IL-8, and Matrix Metalloproteinase-3 Production in Human Synovial Fibroblasts and Enhances Synthesis of Tissue Inhibitors of Metalloproteinases1 , 2000, The Journal of Immunology.

[82]  C. Serhan,et al.  Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking1 , 2000, The Journal of Immunology.

[83]  Hugh R. Brady,et al.  Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages1 , 2000, The Journal of Immunology.

[84]  C. Serhan,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Anti-Inflammatory Actions of Lipoxin A 4 Stable Analogs Are Demonstrable in Human Whole Blood: Modulation of Leukocyte Adhesion Molecules and Inhibition of Neutrophil-Endothelial Interactions , 2016 .

[85]  C. Serhan,et al.  Identification of a human enterocyte lipoxin a receptor that is regulated by IL-13 and IFN-γ and inhibits TNF-α-induced IL-8 release , 1999 .

[86]  C. Clish,et al.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Y. Kaneda,et al.  Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[88]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[89]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[90]  M. Freeman,et al.  Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. , 1999, The Journal of clinical investigation.

[91]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[92]  B. Levy,et al.  Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a ‘stop’ signaling switch for aspirin‐triggered lipoxin A4 , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  C. Serhan,et al.  Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. , 1998, The Journal of clinical investigation.

[94]  C. Serhan,et al.  Identification of a Human Enterocyte Lipoxin A4 Receptor That Is Regulated by Interleukin (IL)-13 and Interferon γ and Inhibits Tumor Necrosis Factor α–induced IL-8 Release , 1998, The Journal of experimental medicine.

[95]  C. Serhan,et al.  Characterization of human neutrophil and endothelial cell ligand-operated extracellular acidification rate by microphysiometry: impact of reoxygenation. , 1998, The Journal of pharmacology and experimental therapeutics.

[96]  C. Clish,et al.  Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. , 1998, The Journal of clinical investigation.

[97]  N. Morris,et al.  The Fate of Cartilage Oligomeric Matrix Protein Is Determined by the Cell Type in the Case of a Novel Mutation in Pseudoachondroplasia* , 1997, The Journal of Biological Chemistry.

[98]  A. M. Lefer,et al.  Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[99]  T. Takano,et al.  Aspirin-triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors , 1997, The Journal of experimental medicine.

[100]  T. Takano,et al.  Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor* , 1997, The Journal of Biological Chemistry.

[101]  J. Cornhill,et al.  Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. , 1996, The Journal of clinical investigation.

[102]  C. Serhan,et al.  Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. , 1996, Journal of immunology.

[103]  C. Serhan,et al.  Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction , 1996, The Journal of experimental medicine.

[104]  G. Majno,et al.  Cells, tissues, and disease : principles of general pathology , 1996 .

[105]  C. Serhan,et al.  Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. , 1995, Biochemistry.

[106]  I. Akritopoulou‐Zanze,et al.  Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. , 1995, Biochemistry.

[107]  C. Serhan,et al.  Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[108]  T. Williams,et al.  Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue, ZK 118.182. , 1994, European journal of pharmacology.

[109]  C. Serhan,et al.  Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. , 1993, The Journal of clinical investigation.

[110]  C. Serhan,et al.  Lipoxin generation by permeabilized human platelets. , 1992, Biochemistry.

[111]  C. Serhan,et al.  Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils , 1990, The Journal of experimental medicine.

[112]  B. Spur,et al.  Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. , 1989, Clinical science.

[113]  M. Brezinski,et al.  Lipoxins stimulate prostacyclin generation by human endothelial cells , 1989, FEBS letters.

[114]  J. Haeggström,et al.  Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. , 1988, Biochemical and biophysical research communications.

[115]  W. Lands,et al.  Proceedings of the AOCS Short Course on Polyunsaturated Fatty Acids and Eicosanoids , 1987 .

[116]  N. Bazan,et al.  Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina. , 1984, Biochemical and biophysical research communications.

[117]  I. Morita,et al.  Increased arachidonic acid content in platelet phospholipids from diabetic patients. , 1983, Prostaglandins, leukotrienes, and medicine.

[118]  B. Samuelsson.  Leukotrienes: a new class of mediators of immediate hypersensitivity reactions and inflammation. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.

[119]  M. Peck,et al.  Mechanisms underlying inflammatory edema: the importance of synergism between prostaglandins, leukotrienes, and complement-derived peptides. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.

[120]  Nobelstiftelsen.  Les Prix Nobel : Nobel Prizes, presentations, biographies and lectures , 1982 .

[121]  P. Ward,et al.  Suppression of acute and chronic inflammation by orally administered prostaglandins. , 1981, Arthritis and rheumatism.

[122]  G. Weissmann,et al.  Release of inflammatory mediators from stimulated neutrophils. , 1980, The New England journal of medicine.